Discovering markers of intra-tumour heterogeneity from the analysis of public cancer genomic data
Heterogeneity between and within tumours are among the major factors underlying drug resistance and tumour relapse. Therefore, it is of paramount importance to find the mechanisms underlying heterogeneity, moving towards more effective treatments. Large Public consortia such as The Cancer Genome Atlas provide patient genomic, clinical and phenotypic data for large cohorts of several different types of cancer. Using data from these large cohorts, we want to discover genomic, clinical and/or phenotypic factors that correlate with measures of intra-tumour heterogeneity. In this talk, I would like to present our initial attempts to do this, and discuss other possible approaches.